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ABSTRACT: Autoreactive B cells are thought to play a pivotal role in many autoimmune diseases. Rheumatoid arthritis (RA)
is an autoimmune disease affecting ∼1% of the Western population and is hallmarked by the presence of anticitrullinated
proteins antibodies (ACPA) produced by autoreactive B cells. We intend to develop a method to target and selectively
eliminate these autoreactive B cells using a sequential antigen prodrug targeting strategy. As ACPA-expressing B cells are
thought to play essential roles in RA-disease pathogenesis, we used this B cell response as a prototype to analyze the feasibility
to generate a construct consisting of a biologically silenced, that is, blocked, antigen connected to a cytotoxic prodrug. Blocking
of the antigen is considered relevant as it is anticipated that circulating autoantibodies will otherwise clear the antigen-prodrug
before it can reach the target cell. The antigen-prodrug can only bind to the autoantigen-specific B cell receptor (BCR) upon
enzymatic removal of the blocking group in close proximity of the B cell surface. BCR binding ultimately induces antigen-
specific cytotoxicity after internalization of the antigen. We have synthesized a cyclic citrullinated peptide (CCP) antigen
suitable for BCR binding and demonstrated that binding by ACPA was impaired upon introduction of a carboxy-p-nitrobenzyl
(CNBz) blocking group at the side chain of the citrulline residue. Enzymatic removal of the CNBz moiety by nitroreductase
fully restored citrulline-specific recognition by both ACPA and ACPA-expressing B cells and showed targeted cell death of
CCP-recognizing B cells only. These results mark an important step toward antigen-specific B cell targeting in general and more
specifically in RA, as successful blocking and activation of citrullinated antigens forms the basis for subsequent use of such
construct as a prodrug in the context of autoimmune diseases.
KEYWORDS: Rheumatoid arthritis, peptidylcitrulline, anticitrullinated protein antibodies, B cell targeting,
antigen silencing and activation
■ INTRODUCTION
Many autoimmune diseases are characterized by the presence
of antibodies that are directed toward self-antigens.1 The
importance of autoreactive B cells in autoimmunity is well
recognized; however, the exact mechanisms of their involve-
ment have not been fully established. Rheumatoid arthritis
(RA) is an inflammatory autoimmune disease that is
characterized by chronic synovitis and erosive destruction of
articular cartilage and bone. RA affects 0.5−1% of adults in the
developed world.2 Of these patients, 70−80% harbor
anticitrullinated protein antibodies (ACPA).3
Protein citrullination, the process where a peptidylarginine is
enzymatically converted into a peptidylcitrulline by peptidy-
larginine deiminase (PAD), is a post-translational modification
commonly observed in inflammation.4 Antibodies directed
toward citrullinated proteins can be detected several years
before the onset of RA, associate with severity of the disease,
and are therefore an interesting marker to predict the
development of RA.5 Cyclic citrullinated peptides (CCPs)
are often used as a test substrate for the detection of ACPA.6
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Depletion of CD20-expressing B cells (e.g., using Ritux-
imab) is effective in treating RA.7 The therapeutic effect is
greater in ACPA-positive RA patients than in the ACPA-
negative counterpart.8 These observations suggest that
autoreactive, ACPA-expressing B cells may play central roles
in driving and maintaining the inflammatory processes in RA.
As CD20-expression by B cells is not restricted to the
autoreactive B cell compartment, depletion of the entire
CD20-positive population by rituximab leads to immune
deficiency against infectious agents.9 Therefore, a strategy to
specifically deplete autoreactive B cells is of great interest. For
example, the use of an autoantigen-toxin conjugate that
selectively targets the BCR can be beneficial.
So far, researchers have used autoantigens as part of specific
targeting strategies for autoreactive B cells. For example,
Reiners and co-workers showed that by using proteinase 3, an
autoantigen in Wegener’s granulomatosis, conjugated to an
angiogenin toxin, proteinase 3-specific B cell hybridomas could
be selectively targeted.10 Similar approaches using alternative
toxins have also been described for the selective targeting of B
cells involved in multiple sclerosis11,12 or B cells producing
antibodies against a tetanus toxoid fragment.13 However, since
specific B cells can differentiate into plasma cells excreting the
same immunoglobulin, antigen-conjugates might be cleared by
these free circulating autoantibodies. To improve B cell
binding in these strategies, we suggest that reduction of
autoantibody-mediated clearance of the autoantigen could be
beneficial.
Here, we aimed to develop a sequential antigen-prodrug
targeting strategy using the archetypic RA-specific autoimmune
response as example, where a specific citrullinated peptide
(cyclic citrullinated peptide, CCP)14−16 was conjugated to a
cytotoxic entity (Figure 1). As CCP is able to bind to ACPA-
expressing B cells and to soluble, free-circulating ACPA, we
introduced a blocking group to circumvent undesired antigen
binding to soluble ACPA upon administration. We envisioned
that the exposure of the citrullinated epitope of the antigen can
be locally restored to ensure high concentrations of the
antigen-drug conjugate in close proximity of ACPA-expressing
B cells (Figure 1). Antigen binding via the specific B cell
receptor followed by internalization of the toxin conjugate
should subsequently result in selective ACPA-positive B cell
death.
We based our approach on the concept of an antibody-
directed enzyme prodrug therapy (ADEPT) as our ultimate
goal for the deprotection of CCP. This strategy has been
explored extensively for local activation of cytotoxic prodrugs
for tumor treatment.17 In an ADEPT strategy, an enzyme is
conjugated to a targeting antibody after which a nontoxic
prodrug is administered. The prodrug is then locally activated
by the enzyme, releasing the toxin specifically at the directed
site. Several enzymes have been explored for this strategy
including alkaline phosphatase,18 beta-lactamase,19 and car-
boxy-peptidase G2.20
In our studies, we focused on using nitroreductase (NTR),
which reduces an aromatic nitro group into an amine (or
hydroxylamine).21 This enzyme has been explored before in
ADEPT strategies, where a potent cytotoxic drug was liberated
in vivo upon reduction of the aromatic nitro group.22,23 In this
and other studies, a nitrobenzyl alcohol protecting group was
Figure 1. Schematic representation of the sequential prodrug strategy. (A) Antigen activation mechanism. NTR reduction of the aromatic nitro
group to the (hydroxyl)amine results in 1,6-elimination of the CNBz blocking group; (B) CArgP and CCP(CNBz) are not recognized by the BCR.
After reduction by NTR, the activated CCP-toxin binds the BCR inducing BCR-mediated internalization and initiation of cell death. (C) Schematic
representation of the CXP peptides used. CCP contains citrulline, CArgP contains arginine, and CCP(CNBz) contains the carboxynitrobenzyl
blocking moiety on the citrulline.
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used as self-immolative linker upon reduction.24−26 We
therefore envisioned that a carboxy-p-nitrobenzyl (CNBz)
would serve as a good blocking group for citrulline and that
reduction by NTR would initiate 1,6-elimination and CO2
release, resulting in a free ureido group at the citrulline side
chain (Figure 1A). In our study, we used NTR as a proof of
concept for selective deprotection of CCP as a prototype
autoantigen, acting on the assumption that this concept can in
the future be implemented into an ADEPT strategy.
■ MATERIALS AND METHODS
Materials. General information on material and methods is
provided in the Supporting Information.
Synthesis. Synthetic procedure for 14-(9H-fluoren-9-yl)-1-
(4-nitrophenyl)-3,5,12-trioxo-2,13-dioxa-4,6,11-triazatetrade-
cane-10-carboxylic acid (1). Fmoc-Cit−OH (2.00 g, 5.03
mmol, 1 equiv) was dissolved in THF (115 mL) and heated to
40 °C. 4-Nitrobenzylchloroformate (1.63 g, 7.55 mmol, 1.5
equiv) was dissolved in THF (5 mL) and added to Fmoc-Cit−
OH. The reaction mixture was stirred overnight. The mixture
was concentrated in vacuo and the mixture was purified over
silica (2.5−5% MeOH in CH2Cl2), yielding a yellow solid
product (1) (948 mg, 77% after regaining starting material). Rf
= 0.49 (5% MeOH in EtOAc). 1H NMR (500 MHz,
Chloroform-d) δ 9.08 (s, 1H), 8.15 (d, J = 8.3 Hz, 2H),
7.93 (s, 1H), 7.73 (d, J = 7.5 Hz, 2H), 7.63−7.52 (m, 2H),
7.43 (d, J = 8.1 Hz, 2H), 7.37 (t, J = 7.3 Hz, 2H), 7.31−7.26
(m, 2H), 5.58 (d, J = 6.2 Hz, 1H), 5.17 (s, 2H), 4.43 (s, 1H),
4.39 (d, J = 6.6 Hz, 2H), 4.19 (t, J = 6.6 Hz, 1H), 3.46−3.11
(m, 2H), 1.98−1.69 (m, 2H), 1.66−1.55 (m, 2H). 13C NMR
(126 MHz, Chloroform-d) δ 176.01, 156.18, 154.74, 153.97,
147.97, 143.75, 142.18, 141.42, 128.40, 127.87, 127.19, 125.19,
123.99, 120.14, 67.07, 66.30, 53.49, 47.32, 39.45, 29.64, 25.51.
HRMS (ESI+) m/z calcd for C29H28N4NaO9
+ [M + Na]+
599.17485, found 599.17540.
General Peptide Synthesis. The first amino acid, Fmoc-
Lys(Mtt)−OH, (2 equiv) was added to the Wang resin with
DIPCDI (2 equiv), HOBt (4 equiv), and DMAP (2 equiv) in
DMF. The mixture was shaken for 16 h at room temperature.
After washing, the Mtt group was cleaved off using 2% TFA in
DCM repeatable for 2 min. After washing with DCM and
DMF, biotin was coupled using DIPCDI (3.3 equiv) and
HOBt (3.6 equiv). Upon completion, the resin was flushed
three times with DMF and piperidine was then added for 30
min to cleave off the Fmoc protecting group. The resin was
subsequently flushed three times with DMF. A mixture of 3
equiv Fmoc-AA−OH, 3.6 equiv HOBt, and 3.3 equiv DIPCDI
was added to the resin to bind the subsequent amino acid. This
reaction was incubated for 30 min at room temperature. After
coupling of the next amino acid, the remaining free amines are
capped with acetic anhydride (1 mL) and pyridine (1 mL) in
DMF (12 mL). After washing three times with DMF,
piperidine was added again and the cycles continued. After
the last amino acid, chloroacetic anhydride (5 equiv) and
DIPEA (5 equiv) were added in DMF and shaken for 45 min.
Finally, a mixture of 92.5% TFA, 2.5% H2O, 2.5% EDT, and
2.5% TIPS was made. This mixture was added to the resin and
incubated for 3 h at room temperature to cleave off the peptide
from the resin and to deprotect the amino acid residues. The
peptide was precipitated in diethyl ether, filtered, and dried.
Kaiser tests were performed to follow the coupling reactions.
General Peptide Cyclization. The crude peptides were
dissolved in a 50 mM NH4HCO3 buffer pH 8.4: MeCN 1:1, at
a concentration of 2 mg/mL and stirred for 24 h. MeCN was
evaporated, and the remaining H2O was lyophilized. The
peptides were purified using preparative reversed-phase HPLC
and analyzed using analytical HPLC.
CArgP1 (2). CArgP1 was synthesized following the
procedures described in the general peptide synthesis. Next,
this peptide was cyclized and purified as described in the
general cyclization method. HPLC: rt. 12.731 min. LC−MS
(ESI+) m/z calcd for C100H172N42O33S2
2+ [M+2H]2+ 1277.13,
found 1277.56. C100H172N41O34S2
3+ [M+3H]3+ 851.75, found
852.28. C100H173N41O34S2
4+ [M+4H]4+ 639.06, found 640.20.
CCP1 (3). CCP1 was synthesized following the procedures
described in the general peptide synthesis. Next, this peptide
was cyclized and purified as described in the general cyclization
method. HPLC: rt. 12.753 min. LC−MS (ESI+) m/z calcd for
C100H171N41O34S2
2+ [M+2H]2+ 1277.61, found 1278.08.
C100H172N41O34S2
3+ [M+3H]3+ 852.07, found 852.68.
C100H173N41O34S2
4+ [M+4H]4+ 639.31, found 641.16.
CCP1(CNBz) (4). CCP1(CNBz) was synthesized following
the procedures described in the general peptide synthesis.
Next, this peptide was cyclized and purified as described in the
general cyclization method. HPLC: rt. 14.854 min. LC−MS
(ESI+) m/z calcd for C108H176N42O38S2
2+ [M+2H]2+ 1367.12,
found 1367.52. C108H177N42O38S2
3+ [M+3H]3+ 911.75, found
912.20. C108H178N42O38S2
4+ [M+4H]4+ 684.06, found 685.20.
CCP1(CNBz) Stability Measurements at Various pH. The
peptide was dissolved in 1% DMSO/McIlvaine buffer (pH 4−
9 at a concentration of 0.2 mg/mL). The reaction was set at 37
°C at 600 rpm for 1−7 days. A sample was taken and was
measured by LC−MS. The area under the curve of the
chromatogram shows the percentage of starting material or
degradation material (CCP1).
Cell Culture and Monoclonal Antibodies. Immortalized B
cell clones recognizing CCP1 and tetanus toxoid (TT) were
generated by transducing antigen-specific human memory B
cells with retroviruses encoding Bcl-6 and Bcl-xL, as previously
described.27,28 Cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 8% heat-
inactivated fetal calf serum, penicillin/streptomycin (PS, 100
U/mL), 2 mM Glutamax, and 1 μg/mL puromycin in the
presence of irradiated CD40L-expressing cells and mouse
interleukin-21-Fc (mIL21-Fc). These B cell clones maintained
the expression of membrane bound ACPA or anti-TT antibody
and also secreted antibodies recognizing CCP1 or TT,
respectively. Supernatants of the cell cultures that contained
secreted monoclonal antibodies against CCP1 or TT were
harvested after 3 days of culture.
RA Plasma. Peripheral blood was obtained from ACPA-
positive RA patients who visited the outpatient clinic of the
Department of Rheumatology at Leiden University Medical
Centre (LUMC). The patients met the 2010 ACR/EULAR
criteria for RA at the time of diagnosis and gave written
informed consent to participate in the study. Permission to
conduct the study was obtained from the ethical review board
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of LUMC. Blood plasma was obtained by centrifuging heparin-
treated peripheral blood.
ELISA Measurements. The ability of the CNBz moiety to
protect CCP1 epitopes from the recognition of both
monoclonal and polyclonal ACPA and the capacity of NTR
to remove the CNBz group and recover CCP1 reactivity were
assessed by ELISA. All reactants were dissolved in PBS pH =
7.4. Ten micromolar (1 equiv) biotinylated CCP1(CNBz) was
treated with 3 μM (0.3 equiv), 1 μM (0.1 equiv), 0.3 μM (0.03
equiv), and 0.1 μM (0.01 equiv) NTR and 50 equiv NADH
(both from Sigma-Aldrich) to test the NTR capacity for 1 h at
37 °C. Next, biotinylated CCP1, CArgP1, CCP1(CNBz), and
NTR-pretreated CCP1(CNBz) were coupled to streptavidin-
coated ELISA plates (C96 Maxisorp Nunc-immuno plate,
Thermo-Scientific). Undiluted supernatants of the immortal-
ized B cell clones and 1:50 diluted patient’s plasma samples
were incubated with the respective antigens; antigen-bound
IgG was detected by polyclonal rabbit antihuman IgG HRP
(DAKO) and stained with ABTS.H2O2 (Sigma-Aldrich) or
TMB-UP (Biomerieux). The absorbance of the colorimetric
signal was measured with iMark TM Microplate Reader
(BioRad) at 415 or 450 nm, respectively.
FACS Measurements. Biotinylated CCP1(CNBz), CCP1,
and CArgP1 were coupled with APC-labeled streptavidin
(Lifetechnologies), as previously described.29 One equivalent
of APC-labeled CCP1(CNBz) tetramer was treated with 0.3
equiv NTR and 50 equiv NADH for 1 h at 37 °C in cell
cultures containing either ACPA-expressing or TT-specific
immortalized B cells in a 96-well plate. Subsequently, the cells
were kept on ice for 30 min, washed, resuspended with 1%
paraformaldehyde, and measured by flow cytometry using BD
LSRFortessa (BD Biosciences).
Cell Viability Assay. Biotinylated CCP1, CArgP1, and
CCP1(CNBz) were conjugated with streptavidin-saporin
(Advanced Targeting systems) in a 4:1 ratio to make
peptide-drug conjugates. The 1 ×104 ACPA-expressing or
TT-specific B cell clones were cultured with medium, mIL21-
Fc, and soluble CD40L (from Biolegend) in the presence of 0,
0.1, 1, 10, 100 nM peptide-drug conjugates in a 96-well plate.
After 4 days, supernatants were collected and XTT labeling
and electron-coupling reagents (Roche) were added to the
culture according to the manufacturer’s protocol and incubated
for 6 h. Cell viability was measured on a iMark TM Microplate
Reader (from BioRad).
■ RESULTS AND DISCUSSION
Synthesis of (Blocked) Citrullinated Antigens. We
started our studies by exploring a synthetic strategy to generate
a blocked cyclic citrullinated peptide (CCP) antigen. As the
citrulline residue is key for recognition by ACPA and citrulline-
directed BCRs, we envisioned that the ureido moiety of the
citrulline residue itself would be the best position to introduce
Figure 2. ACPA binding toward (blocked) CCP1 and antigen activation using NTR. (A) Structures of CArgP1 (2), CCP1 (3), and the CNBz
protected CCP1 (4). Biotin is used for conjugation purposes; (B) CCP1 ELISA using protected antigens detected by monoclonal ACPA. One hour
incubation of the protected peptide with different NTR concentrations fully restored ACPA binding. Abs: absorbance at 450 nm. Experiment is
performed twice in triplicate.
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the blocking group. The required building block needed for
solid phase peptide synthesis (SPPS) of the blocked CCP was
obtained by reacting Fmoc-citrulline with para-nitrophenyl-
chloroformate in THF in reasonable yield after recovery of the
unreacted starting material (Supplementary Scheme S1). The
carboxy-p-nitrobenzyl modified Fmoc-citrulline (1) proved
very stable toward 20% piperidine and TFA and could thus be
used in SPPS to produce the full CCP antigen.
We selected a cyclic citrullinated peptide 1 (CCP1)
analogue, a well-known ACPA antigen,14,16 as initial antigen
for our conjugate assembly (Figure 2). CCP1 is recognized by
37−62% of ACPA-positive sera,16 whereas the arginine
containing variant of the peptide (CArgP1) does not have
affinity for ACPA and can therefore serve as a negative control.
CXP1 peptides (with X being different amino acids) were
synthesized using standard Fmoc SPPS with arginine (2,
CArgP1) as the negative control, citrulline (3, CCP1) as the
positive control and protected citrulline 1 (4, CCP1(CNBz))
(Figure 2A). The CNBz-protected variant of CCP1 proved to
be stable for at least 7 days in acidic to neutral pH
(Supplementary Figure S1). A biotin moiety was installed at
the single free amine functionality on resin for further
experimental evaluation. The CXP1 peptides were covalently
cyclized by first reacting the N-terminus with chloroacetic
anhydride followed by deprotection of the full peptide and
substitution of the chloride by the internal cysteine.
NTR-Mediated Deprotection of CCP1(CNBz). Having
the biotinylated controls and blocked CXP1 antigens 2−4 in
hand, we explored the rate of CNBz removal by NTR. We first
established that removal of the CNBz moiety from the citrulline
building block 1 was fast and full removal was observed within
5 min using 0.3 equiv NTR and NADH as cofactor as
evidenced by analytical HPLC analysis (Figure S2). Next, we
evaluated whether the CNBz group blocked the CCP1 antigen
from binding to ACPA in an enzyme-linked immunosorbent
assay (ELISA) using monoclonal ACPA obtained from the
supernatant of ACPA-producing immortalized B cells. These
ACPA-expressing B cells were previously isolated from an
ACPA-positive RA patient and transduced with BCL-XL, BCL-
6, and GFP genes resulting in ACPA-secreting and -expressing,
GFP-positive immortalized B cells.30 Biotinylated and
protected peptide 4 as well as control peptides 2 and 3 were
coupled to a streptavidin-coated ELISA plate and incubated
with monoclonal ACPA-containing supernatant. Removal of
the CNBz group was performed before coupling of the peptide
to the ELISA plate. Figure 2B shows that monoclonal ACPA
recognize CCP1, as expected. More importantly, the CNBz
group on CCP1 blocked monoclonal ACPA-binding to the
level observed for the negative control peptide (CArgP1 2).
Figure 3. ELISA with the CXP1 antigens incubated with ACPA-positive patient sera. 0.3 equiv nitroreductase (NTR) was used for antigen
activaion. Anti-Tetanus toxoid (TT) antibodies are used as negative control. Abs: absorbance at 415 nm. This experiment was performed in
duplicate.
Figure 4. Flow cytometric binding studies of streptavidin-coupled, biotinylated CCP1, CArgP1, and (activated) CCP1(CNBz) to (A) ACPA-
expressing B cell clone and (B) TT-specific B cell clone. This experiment was performed twice.
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Treatment of CCP1(CNBz) with NTR and NADH as a
cofactor for 1 h at 37 °C in PBS pH 7.4 showed a
concentration-dependent antigen activation, as evidenced by
restoration of the binding to the monoclonal ACPA. As
observed previously, full restoration of the CCP1 antigen was
already achieved within 5 min using 0.3 equiv NTR (Figure
S3).
As ACPA present in blood of RA-patients are not
monoclonal,31 we next investigated the recognition of these
peptides by patient sera. We selected sera of five different
patients that were highly positive for antibodies to CCP2, the
common antigen used for the detection of ACPA in a clinical
diagnostic setting. Four of these RA patients were highly
positive and one weakly positive for CCP1 recognition (Figure
3). The CArgP1 negative control was not bound by patient
ACPA, and, similarly, no recognition of CCP1(CNBz) antigen
was observed. Activation of the antigen using 0.3 equiv NTR
resulted in the full recovery of initial binding toward the
polyclonal ACPA for all five patients showing that both
blocking and activation of CCP1 for recognition by patient
derived polyclonal ACPA is feasible.
Antigen-Dependent Selective Cellular Targeting and
Toxicity. Application of the sequential antigen prodrug
targeting strategy presented here requires efficient antigen
activation in the proximity of cells. To this end, biotinylated
CXP1 antigens were conjugated to fluorescently labeled
streptavidin tetramers to visualize antigen binding to B cells
by flow cytometry.32 Two B cell clones derived from
immortalized ACPA-expressing and tetanus toxoid (TT)-
specific primary B cells were used for this purpose. The
antigen specificity of the immortalized B cell clones is shown in
Figure S4.
Figure 4A shows staining of CCP1-streptavidin-APC
conjugates (y-axis) to clonal ACPA-expressing immortalized
B cells (GFP-positive, x-axis), indicating binding of CCP1-
streptavidin tetramers to cell surface BCRs. No binding was
observed for the CArgP1 and CCP1(CNBz) antigen variants,
demonstrating specificity of the signals observed for CCP1.
Notably, addition of 0.3 equiv NTR for 1 h almost completely
recovered antigen-binding to ACPA-expressing B cells (last
panel), while no binding was observed to TT-specific control B
cell clones (Figure 4B). Together, these data indicate that
blocking and activation of CCP1 can be achieved for antigen-
specific recognition by both soluble antibodies and surface-
expressed B cell receptors.
To demonstrate that restored antigen-recognition by B cells,
could also result in selective killing of ACPA-expressing B cells,
we conjugated the biotinylated antigen variants to a
streptavidin-saporin conjugate (SA-ZAP, Figure 5A and
B).33,34 Saporin is a cytotoxic ribosome inhibitor that induces
cell death by apoptosis,35 which has been used in many in vivo
studies as antibody-drug conjugate.36−40 Equal numbers (1 ×
104) of ACPA-expressing and TT-specific immortalized B cells
were cultured with 0, 0.1, 1, 10, and 100 nM antigen-SA-ZAP
conjugates. After 4 days of incubation, a XTT cell viability
assay was performed to assess the amount of remaining viable
cells. The percentage of living cells was calculated by dividing
the optical density value of cells treated with antigen-SA-ZAP
by the optical density of cells treated in parallel with the
corresponding antigen-SA complex. Figure 5C and D show the
percentage of living ACPA-expressing B cells or TT-expressing
B cells, respectively, after treatment with SA-ZAP conjugated
to CXP1 either treated or nontreated with NTR.
The exposure of cells to CCP1-SA-ZAP at 1 nM as well as
the activated CCP1(CNBz) induced death of up to 60% of
ACPA-expressing B cells. At this SA-ZAP concentration, 96%
of ACPA-expressing B cells survived the treatment when
bound to CCP1(CNBz), comparable to CArgP1-SA-ZAP or
SA-ZAP without peptide. Increasing the concentration resulted
in further increased cell death, although increasing cellular
toxicity was then also noted for SA-ZAP that was not
conjugated to any antigen (Figure 5C). The lack of 100%
Figure 5. Selective cytotoxicity by enzymatic activation of CCP1-SA-ZAP conjugates. Schematic representation of streptavidin-ZAP bound to the
CXP1 peptides (A) and the expected toxicity of the different SA-ZAP conjugates to ACPA expressing B cells (B). Percentage of living ACPA-
expressing B cells (C) and TT-specific B cells (D) after 4 days of treatment with antigen-toxin conjugates.
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death of ACPA-expressing B cell clone by either CCP1-SA-
ZAP or NTR-treated CCP1(CNBz)-SA-ZAP could relate to
the transfection of these cells with antiapoptotic genes, which
might make them less susceptible to toxic agents than would
be for conventional B cells.
As the antigen-toxin conjugate, once it is activated by
nitroreductase, can bind to both the B cell receptor of ACPA-
expressing cells and to secreted ACPA molecules, we consider
it important that deprotection eventually occurs in close
vicinity to the B cell receptor that we envision to be achieved
by an ADEPT approach. Nonetheless, binding of secreted
ACPA molecules to the conjugate could lead to the formation
of immune complexes. Circulating ACPA-immune complexes
have been reported to be capable of stimulating effector cells in
vitro via binding to Fc receptors.41 Thus, Fc receptor-mediated
effects such as antibody dependent cellular cytotoxicity cannot
be fully excluded and future in vivo studies will have to be
performed to evaluate this possibility.
Finally, the selectivity of the approach was demonstrated by
the lack of toxicity of the conjugates for TT-specific B cells
(Figure 5D), and also NTR by itself did not show toxic effects
on the B cells used (Figure S5). These results indicate that
CCP1-SA-ZAP and NTR-treated CCP1(CNBz)-SA-ZAP can
be used for the selective depletion of ACPA-expressing B cells
ex vivo.
■ CONCLUSIONS
The high specificity of the ACPA immune response for RA, the
therapeutic efficacy of CD20 depletion in the treatment of this
disease, and the risks of long-lasting systemic immunosup-
pression associated with this treatment have fueled efforts
aimed at the selective elimination of ACPA-expressing memory
B cells as a prospect of targeted therapy in RA. Here, we
demonstrate a sequential two-step prodrug strategy to
selectively eliminate autoreactive B cells. By exploiting the
essential requirement of the citrulline residue in the antigen for
recognition by ACPA-BCR and soluble ACPA molecules, we
showed that blocking this amino acid with CNBz resulted in
complete loss of binding toward ACPA and ACPA expressing
B cells. Furthermore, the CNBz group could be removed by
nitroreductase to restore binding of the antigen. Using this
strategy, we selectively induced cell death in immortalized
ACPA expressing B cell clones using an antigen coupled to a
streptavidin-toxin, while TT-expressing B cells were insensitive
to these conjugates.
We expect that removal of the blocking group in close
proximity to the B cell membrane, for example, by using NTR,
can circumvent binding of antigen to free circulating ACPA,
thereby decreasing the risk for rapid clearance of the drug from
tissue and the circulation. The CNBz removal using NTR may
be beneficial as elevated levels of reductases are found in
hypoxic inflamed tissue.42 In addition, NTR has been explored
previously in ADEPT23 and enzyme-selective cofactors for E.
coli NTR are reported circumventing the use of serum-sensitive
cofactors such as NAD(P)H.43
In conclusion, we show that we can selectively control the
reconition of CCP1, thereby tuning the affinity toward ACPA
and ACPA expressing B cells. Using this approach, we
circumvent CCP1(CNBz) from binding to ACPA and regain
binding to the BCR after selective deprotection by NTR in the
proximity of B cells, using a possible ADEPT construct. Since
not all autoreactive B cells reside in inflamed tissue, but also in
lymph nodes, we currently investigate additional approaches
for the selective deprotection of target antigens including so-
called ‘click to release chemistry’.44 In this study, we
demonstrated the blocking and antigen activation in the
context of the citrulline-specific B cell response, but we expect
that this modular strategy will be applicable interchangeably for
other (auto)antigens. The selectivity of the antigen and the
possibility to block binding toward circulation ACPA brings us
a step closer to the specific elimination of autoreactive B cells
for the treatment of patients with ACPA-positive RA.
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